

RealRate Inc., 2040 Martin Ave., Santa Clara, CA 95050



RealRate

July 10, 2026

To the CEO
Jazz Pharmaceuticals plc
FIFTH FLOOR, WATERLOO EXCHANGE
WATERLOO ROAD
DUBLIN, D04 E5W7
USA

Jazz Pharmaceuticals plc TOP Rated in the US Pharmaceutical Ranking

Dear Sir or Madam,

at RealRate we have just published the 2026 US Pharmaceutical ranking. I am happy to inform you that Jazz Pharmaceuticals plc has been TOP Rated at rank 21 out of 178.

Overall, 178 US companies were analyzed with respect to their financial strength. The complete rating is published at <https://www.realrate.ai/rankings>. Your individual rating report, showing your strengths compared to your competitors is attached.



RealRate is an international rating agency based in Santa Clara and Berlin. We use artificial intelligence to create fair and explainable company ratings. Customers highly appreciate the RealRate rating seal: only the strongest companies are able to offer highly attractive and innovative products with top customer services. Billion dollar companies rely on our rating and build trust with their customers.

You too can acquire the RealRate seal and advertise with it. We only reach out to the top-rated companies, like yours and only those may subscribe for our seal. Save a lot of money and effort compared to traditional rating agencies: get a RealRate seal for just \$9,900. Simply sign the attached order form and send it back via email.

Please feel free to book a short video call with me: <https://calendly.com/holger-bartel>


Sincerely,

Dr. Holger Bartel, CEO

RealRate Seal Subscription

RealRate Inc.
2040 Martin Ave., Santa Clara, California 95050, USA
Via email to: holger.bartel@realrate.ai

We subscribe to the Pharmaceutical RealRate rating for Jazz Pharmaceuticals plc. The subscription comprises the annual rating update. The invoice will be sent annually, provided that a TOP rating is achieved again. The subscription can be cancelled by written letter, effective for the following year.



RealRate provides the rating seal as a scalable vector graphic. It can be used without any restrictions by Jazz Pharmaceuticals plc (Customer) for all promotional purposes, i.e. in product brochures, presentations, websites and broadcasting.

Item	2026 US Pharmaceutical RealRate rating seal for Jazz Pharmaceuticals plc
Amount	USD 9,900
Order no.	2026-0001232524

Amounts payable by Customer are exclusive of taxes. Customer is responsible for all his taxes and will pay such amounts invoiced by RealRate.

Billing address


Company name	Full name
Street address	Department
City	Phone number
State / province	Email address
ZIP code	
Country	

Shipping address

The electronic RealRate rating seal and the invoice will be sent to
Delivery email

Jazz Pharmaceuticals plc

Date, location, name



The relative strengths and weaknesses of Jazz Pharmaceuticals plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Jazz Pharmaceuticals plc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 99% points. The greatest weakness of Jazz Pharmaceuticals plc is the variable Assets, Current, reducing the Economic Capital Ratio by 12% points.

The company's Economic Capital Ratio, given in the ranking table, is 364%, being 135% points above the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	4,166,043
Cost of Goods Sold	0
Intangible Assets	6,258,850
Liabilities, Current	2,242,521
Liabilities, Non-Current	0
Other Assets	1,234,447
Other Compr. Net Income	379,069
Other Expenses	885,514
Other Liabilities	0
Other Net Income	-198,351
Other Revenues	4,267,586
Property and Equipment	0
Research and Development	1,730,598
Selling, General and Administrative Expense	1,809,271

Output Variable	Value in 1000 USD
Assets	11,659,340
Liabilities	2,242,521
Expenses	4,425,383
Revenues	4,267,586
Stockholders Equity	9,416,819
Net Income	-356,148
Comprehensive Net Income	-166,614
BaseVar	11,586,125
ECR before Limited Liability	293%
Economic Capital Ratio	364%